Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

R95

—

048cc214-e5a0-51a9-95c9-80c4de42b7a8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
overall_survival_months
6
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.400
  • HEDGEHOG_SIGNALING+0.390
  • COAGULATION+0.300
  • OXIDATIVE_PHOSPHORYLATION+0.290
  • PANCREAS_BETA_CELLS+0.290
  • E2F_TARGETS+0.270
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
  • SPERMATOGENESIS+0.240
  • ALLOGRAFT_REJECTION+0.190
  • MYOGENESIS+0.180

Top 10 suppressed

  • ESTROGEN_RESPONSE_LATE-0.290
  • ESTROGEN_RESPONSE_EARLY-0.210
  • TGF_BETA_SIGNALING-0.210
  • PEROXISOME-0.200
  • PROTEIN_SECRETION-0.200
  • ANDROGEN_RESPONSE-0.190
  • UV_RESPONSE_DN-0.190
  • P53_PATHWAY-0.170
  • PI3K_AKT_MTOR_SIGNALING-0.150
  • XENOBIOTIC_METABOLISM-0.150

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-AC-A7VC-01A-11R-A352-07
breast-umap@18
—A0.695
2TCGA-A2-A3XX-01A-21R-A239-07
breast-umap@18
—E0.682
3MNG1130
mng-umap@100
——0.676
4TCGA-BH-A0E6-01A-11R-A034-07
breast-umap@18
—E0.669
5MBCProject_0852_T2_RNA
breast-umap@18
—E0.667
6SRR33532779
breast-umap@18
—A0.653
7TCGA-OL-A5S0-01A-11R-A28M-07
breast-umap@18
—E0.639
8DRR168594
bladder-landscape@3
——0.636
9TCGA-AO-A12F-01A-11R-A115-07
breast-umap@18
—E0.635
10TCGA-85-8276-01A-11R-2296-07
lung-landscapes@6
—cohortSQ10.634

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.400Idelalisib— uncovered
HEDGEHOG_SIGNALING0.390Inavolisib— uncovered
COAGULATION0.300Binimetinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.290Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.290Cobimetinib— uncovered
E2F_TARGETS0.270Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.240Inavolisib— uncovered
SPERMATOGENESIS0.240Inavolisib— uncovered
ALLOGRAFT_REJECTION0.190Idelalisib— uncovered
MYOGENESIS0.180Inavolisib— uncovered
ANGIOGENESIS0.170Remibrutinib— uncovered
G2M_CHECKPOINT0.150Inavolisib— uncovered
MTORC1_SIGNALING0.140Inavolisib— uncovered
MYC_TARGETS_V10.130Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.110Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.100Remibrutinib— uncovered
UV_RESPONSE_UP0.080Idelalisib— uncovered
GLYCOLYSIS0.070Inavolisib— uncovered
COMPLEMENT0.060Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.060Inavolisib— uncovered